[Clinical Utility of Circulating Tumor DNA Analysis for Precision Medicine in Patients with Advanced Gastrointestinal Cancer].

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

[Clinical Utility of Circulating Tumor DNA Analysis for Precision Medicine in Patients with Advanced Gastrointestinal Cancer].

Gan to kagaku ryoho. Cancer & chemotherapy - 1 Oct 2021

Nakamura Yoshiaki

Abstract excerpt

To implement cancer precision medicine based on genomic alterations, tumor tissue genomic profiling using next generation sequencing(NGS)has been reimbursed in 2019, resulting in simultaneous measurement of multiple biomarkers and genomic abnormalities in clinical practice in Japan. However, NGS analysis of tumor tissue has several limitations, including long turnaround time, and difficulty in capturing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Circulating Tumor DNA
Share to Gastrointestinal Neoplasms
Share to High-Throughput Nucleotide Sequencing
Share to Mutation
Share to Precision Medicine

Source

Open in PubMed

Identifiers

PMID: 34657046

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics